Targeting the IL-17A pathway for therapy in early-stage tendinopathy.

ABSTRACT:

Objectives

Tendinopathy is a frequent clinical problem and represents an extraordinary health economic and socioeconomic burden with high unmet medical needs. Recent clinical evidence suggests blockade of interleukin 17A (IL-17A) for tendinopathy therapy. The present preclinical study elucidates the biological mechanisms of IL-17A pathway stimulation and blockade in tendinopathy.

Methods

We explored whether IL-17A and other IL-17 family members are differentially expressed in biopsies of healthy, early-stage and late-stage tendinopathic human rotator cuff tendons using RT-qPCR. IL-17 pathway signature genes in healthy human tendon-derived cells were identified following IL-17A stimulation using AmpliSeq RNA. The molecular, structural and functional consequences of IL-17A pat

SUBMITTER: Millar NL 

PROVIDER: S-EPMC11881027 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature